{
    "clinical_study": {
        "@rank": "77132", 
        "arm_group": [
            {
                "arm_group_label": "PDC-1421", 
                "arm_group_type": "Experimental", 
                "description": "Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days."
            }, 
            {
                "arm_group_label": "Placebo control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject,\n      find the effective adequate dose for the next stage of the study, and accumulate information\n      of possible mechanism of its anti-depressive effect."
        }, 
        "brief_title": "A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 20-65 years.\n\n          2. Subjects must be able to understand and willing to sign informed consent.\n\n          3. Female subjects of child-bearing potential must test negative to pregnancy and use\n             appropriate birth control method from the beginning of study to the 15 days later\n             after ending of study.\n\n          4. Laboratory data: red blood cell count(RBC),white blood cell count(WBC), platelets,\n             hematocrit, hemoglobin, prothrombin time(PT), partial thromboplastin time\n             (aPTT),aspartate transaminase(AST),alanine aminotransferase(ALT), Lactate\n             dehydrogenase(LDH), total bilirubin, blood urea nitrogen(BUN),serum creatinine, free\n             thyroxine (FT4), thyroid-stimulating hormone (TSH) level,sodium, potassium, calcium,\n             glucose, are all within the normal range.\n\n          5. No significantly abnormal findings on physical examination, ECG and vital sign.\n\n        Exclusion Criteria:\n\n          1. With any clinically significant neurological, gastrointestinal, renal,\n             hepatic,cardiovascular, respiratory, metabolic, endocrine, hematological or other\n             major disorders as determined by the Investigator.\n\n          2. A positive drug screen.\n\n          3. Any mental disorder diagnosed by board-certificated psychiatrist through detailed\n             diagnostic interview.\n\n          4. Any history of suicidal behavior in the past 6 months when evaluated by the C-SSRS.\n\n          5. The intensity of suicidal ideation in the past 6 months is no less than 4 defined by\n             the C-SSRS.\n\n          6. Have received any prescribed medicine, investigational drug or any non prescribed\n             medicine (including herbal remedies) with 14 days prior to enroll this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774045", 
            "org_study_id": "Phase I  study of PDC-1421"
        }, 
        "intervention": [
            {
                "arm_group_label": "PDC-1421", 
                "intervention_name": "PDC-1421", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo control", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Major depressive disorder", 
            "Depression"
        ], 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "contact": {
                "email": "sonnywu@bioliteinc.com", 
                "last_name": "Hsien-Ming Wu", 
                "phone": "886-3-578-6976", 
                "phone_ext": "11"
            }, 
            "contact_backup": {
                "email": "lauryn1022@bioliteinc.com", 
                "last_name": "Yu-Han Lee", 
                "phone": "886-2-8751-8701", 
                "phone_ext": "22"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "112"
                }, 
                "name": "Taipei Veterans General Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Cheng-Ta Li, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Tung-Ping Su, M.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers", 
        "overall_official": [
            {
                "affiliation": "Taipei Veterans General Hospital, Taiwan", 
                "last_name": "Cheng-Ta Li, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Taipei Veterans General Hospital, Taiwan", 
                "last_name": "Tung-Ping Su, M.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration", 
                "Taiwan: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety endpoint is based on the measurement of physical examination, vital signs,laboratory data, Electrocardiograph(ECG), Columbia-Suicide Severity Rating Scale (C-SSRS) evaluation and number of adverse events(AEs) and serious adverse events (SAEs) during the study period.", 
            "measure": "Physical examination, Vital sign, ECG, Hematology, Blood chemistry, AEs/SAEs monitoring, C-SSRS", 
            "safety_issue": "Yes", 
            "time_frame": "observe for 72hr after taking drugs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "BioLite, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioLite, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}